Türk Populasyonunda Şizofreni Hastalığı İçin Bir Risk Faktörü Olarak Adenozin Deaminaz
Geni G22a Polimorfizmi
Amaç: Bu çalışmanın amacı, adenozin deaminaz (ADA) genindeki G22A polimorfizminin Türk popülasyonunda şizofreni ile ilişkisinin araştırılmasıdır. Yöntemler: Bu çalışmada biz 113 şizofreni tanısı almış hasta ve 121 sağlıklı kontrol bireylerini inceledik. ADA geni G22A polimorfizmi allel spesifik-polimeraz zincir reaksiyonu (AS-PCR) yöntemi kullanılarak belirlendi. Bulgular: ADA genindeki G22A polimorfizmi için GG, GA ve AA genotip sıklıkları sırası ile kontrol grubu için %79.3 (96/121), %20,3 (25/121), %0 (0) ve hasta grubu için %87,6 (99/113), %10,6 (12/113), %1,8 (2/113) olarak belirlendi. Genotip dağılım bakımından hasta ve kontrol grupları arasında anlamlı fark bulundu (p=0,017). Ayrıca GA genotipinin sıklığı hastalarda kontrole nazaran anlamlı düzeyde düşük bulundu (p=0,048, OR=0.46, 95%CI 0.22- 0.96). Fakat allel sıklıkları bakımından iki grup arasında anlamlı fark bulunamadı. Cinsiyet bakımından karşılaştırma yaptığımız zaman, erkek hastalarda GG genotipinin anlamlı düzeyde yüksek, GA genotipinin ise düşük olduğu gözlendi (sırası ile p=0,036 ve p=0,005). Kadın hastalarda herhangi bir anlamlı fark gözlenmedi. Sonuç: Bizim sonuçlar ADA genindeki G22A polimorfizminin Türk popülasyonunda şizofreni hastalığı ile ilişkili olabileceğini gösterdi. ADA genindeki GA genotipinin özellikle erkeklerde şizofreniye yatkınlığı düşürdüğü, buna karşın GG genotipinin yatkınlığı arttırdığı muhtemeldir. Farklı hasta ve etnik gruplar ile gelecekte yapılacak çalışmalar, elde ettiğimiz sonuçların kesinleşmesine yardımcı olur
Adenosine Deaminase Gene G22a Polymorphism as a Risk Factor for Schizophrenia
in Turkish Population
Objective: The aim of this study was to investigate whether the G22A polymorphism of adenosine deaminase (ADA) gene is associated with schizophrenia in Turkish population. Methods: In this study, we evaluated 113 patients with schizophrenia and 121 individuals without the disease. The ADA G22A polymorphism was examined using allele specific-polymerase chain reaction (PCR). Results: The ADA G22A genotype frequencies of GG, GA, and AA were 79.3% (96/121), 20.7% (25/121) and 0% (0) in the control group, while 87.6 % (99/113), 10.6% (12/113), 1.8% (2/113) in the patient group, respectively. There was a statistically significant difference in genotype distribution between patients and controls (p=0.017). Also the frequency of GA genotype was found significantly lower in patients compared with healthy controls (OR = 0.46, 95% Cl 0.22-0.96, p =0.048). However, there was not any noticeable difference in allele distribution between the groups (p>0.05). In addition, the frequency of GG genotype in the male patient group significantly higher, and GA genotype significantly lower compared to the male control group, were found (p=0.036, p=0.005, respectively). No association was found for the female group. Conclusion: Our results show that, the G22A polymorphism of ADA gene may be associated with schizophrenia in Turkish population. The ADA GA genotype is likely to reduce, whereas GG genotype increased genetic susceptibility to schizophrenia, especially in males. Further studies should be repeated with different study subjects and/or other ethnic subjects to generalize the conclusion of this study.
___
- 1. Zhang L, Zhong X, An Z, et al. Association analysis of the
GRM8 gene with schizophrenia in the Uygur Chinese population.
Hereditas 2014;151:140-144.
- 2. El-Hadidy MA, Abdeen HM, Abd El-Aziz SM, et al. MTHFR
gene polymorphism and age of onset of schizophrenia
and bipolar disorder. Biomed Res Int 2014;2014:318483.
- 3. Dutra GP, Ottoni GL, Lara DR, et al. Lower frequency of the
low activity adenosine deaminase allelic variant (ADA1*2)
in schizophrenic patients. Rev Bras Psiquiatr 2010;32:275-
278.
- 4. Nunes DP, Spegiorin LC, Mattos CC, et al. The ADA*2 allele
of the adenosine deaminase gene (20q13.11) and recurrent
spontaneous abortions: an age-dependent association.
Clinics (Sao Paulo) 2011;66:1929-1933.
- 5. Hettinger JA, Liu X, Holden JJ. The G22A polymorphism of
the ADA gene and susceptibility to autism spectrum disorders.
J Autism Dev Disord 2008;38:14-19.
- 6. Takhshid MA, Zahediannejad Z, Aboualizadeh F, et al.
G22A Polymorphism of adenosine deaminase and its association
with biochemical characteristics of gestational
diabetes mellitus in an Iranian population. Iran J Med Sci.
2015;40:170-174.
- 7. Camargo U, Toledo RA, Cintra JR, et al. Lack of association
of the G22A polymorphism of the ADA gene in patients
with ankylosing spondylitis. Genet Mol Res 2012;11:1178-
1184.
- 8. Battistuzzi G, Iudicone P, Santolamazza P, et al. Activity of
adenosine deaminase allelic forms in intact erythrocytes
and in lymphocytes. Ann Hum Genet 1981;45:15-19.
- 9. Washington, DC: American Psychiatric Association; 2000.
American Psychiatric Association, editor. Diagnostic and
Statistical Manual of Mental Disorders.
- 10. Sun YJ, Yu Y, Zhu GC, et al. Association between single
nucleotide polymorphisms in MiR219-1 and MiR137 and
susceptibility to schizophrenia in a Chinese population.
FEBS Open Bio 2015;5:774-778.
- 11. Consortium. Schizophrenia Working Group of the Psychiatric
Genomics Biological insights from 108 schizophreniaassociated
genetic loci. Nature 2014;511:421-427.
- 12. Schmidt A, Böhmer AE, Antunes C, et al. Anti-nociceptive
properties of the xanthine oxidase inhibitor allopurinol
in mice: role of A1 adenosine receptors. Br J Pharmacol
2009;156:163-172.
- 13. Brunstein MG, Ghisolfi ES, Ramos FL, et al. A clinical trial
of adjuvant allopurinol therapy for moderately refractory
schizophrenia. J Clin Psychiatry 2005;66:213-219.
- 14 .Boison D, Singer P, Shen HY, et al. Adenosine hypothesis
of schizophrenia--opportunities for pharmacotherapy. Neuropharmacology.
2012;62:1527-1543.
- 15. Demirci K, Özçankaya R, Yilmaz HR, et al. Paliperidone
regulates intracellular redox system in rat brain: Role of purine
mechanism. Redox Rep 2015;20:170-6.
- 16. Lara DR, Dall’Igna OP, Ghisolfi ES, et al. Involvement
of adenosine in the neurobiology of schizophrenia and its
therapeutic implications. Prog Neuropsychopharmacol Biol
Psychiatry 2006;30:617-629.
- 17. Sebastião AM, Ribeiro JA. Adenosine receptors and the central
nervous system. Handb Exp Pharmacol 2009;193:471–
534.
- 18. Shen HY, Singer P, Lytle N, et al. Adenosine augmentation
ameliorates psychotic and cognitive endophenotypes
of schizophrenia. J Clin Invest 2012;122:2567-2577.
- 19. Akkoç H, Kelle I, Kale E, et al. The Effects of Ischemic
Preconditioning on Cardiac Ischemia-Reperfusion Injury in
Rat Lung. Dicle Med J 2008;35:102-109.
- 20. Boison D. Modulators of nucleoside metabolism in the therapy
of brain diseases.Curr Top Med Chem. 2011;11:1068-
1086.
- 21. Yee BK, Singer P, Chen JF, et al. Transgenic overexpression
of adenosine kinase in brain leads to multiple learning impairments
and altered sensitivity to psychomimetic drugs.
Eur J Neurosci. 2007;26:3237-3252.
- 22. Gotoh L, Mitsuyasu H, Kobayashi Y, et al. Association
analysis of adenosine A1 receptor gene (ADORA1) polymorphisms
with schizophrenia in a Japanese population.
Psychiatr Genet. 2009;19:328-335.
- 23. Lalande D, Thériault L, Kalinova É, et al. The effect of exercise
on sleep quality and psychological, physiological,
and biological correlates in patients with schizophrenia: A
pilot study. Schizophr Res 2016;Mar;171:235-236.
- 24. Garcia-Rill E, D’Onofrio S, Mahaffey S, et al. Pedunculopontine
arousal system physiology-Implications for schizophrenia.
Sleep Sci 2015;8:82-91.
- 25. Basheer R, Strecker RE, Thakkar MM, et al. Adenosine and
sleepwake regulation. Prog Neurobiol 2004;73:379-396.
- 26. Rétey JV, Adam M, Honegger E, et al. A functional genetic
variation of adenosine deaminase affects the duration and
intensity of deep sleep in humans. Proc Natl Acad Sci USA
2005;102:15676-15681.
- 27. Stubbs G, Litt M, Lis E, J et al. Adenosine deaminase activity
decreased in autism. J Am Acad Child Psychiatry
1982;21:71-74.
- 28. Zoroglu SS, Armutcu F, Ozen S, et al. Increased oxidative
stress and altered activities of erythrocyte free radical scavenging
enzymes in autism. Eur Arch Psychiatry Clin Neurosci
2004;254:143-147.
- 29. Herken H, Akyol O, Yilmaz HR, et al. Nitric oxide, adenosine
deaminase, xanthine oxidase and superoxide dismutase
in patients with panic disorder: alterations by antidepressant
treatment. Hum Psychopharmacol 2006;21:53-59.
- 30. Yolaç Yarpuz A, Yilmaz A, et al. Levels of adenosine deaminase
and dipeptidyl peptidase IV in patients with panic
disorder .Turk Psikiyatri Derg. 2008;19:149-156.
- 31. Herken H, Gurel A, Selek S, et al. Adenosine deaminase,
nitric oxide, superoxide dismutase, and xanthine oxidase
in patients with major depression: impact of antidepressant
treatment. Arch Med Res. 2007;38:247-252.
- 32. Elgün S, Keskinege A, Kumbasar H. Dipeptidyl peptidase
IV and adenosine deaminase activity. Decrease in depression.
Psychoneuroendocrinology 1999;24:823-832.
- 33. Brunstein MG, Silveira EM Jr, Chaves LS, et al. Increased
serum adenosine deaminase activity in schizophrenic
receiving antipsychotic treatment. Neurosci Lett
2007;414:61-64.
- 34. Concetti F, Carpi FM, Nabissi M, et al. The functional polymorphism
rs73598374:G>A (p.Asp8Asn) of the ADA gene
is associated with telomerase activity and leukocyte telomere
length. Eur J Hum Genet 2015;23:267-270.
- 35. Bottini N, De Luca D, Saccucci P, et al. Autism: evidence
of association with adenosine deaminase genetic polymorphism.
Neurogenetics 2001;3:111-113.
- 36. Tavilani H, Sheikh N, Vaisi-raygani A, et al. Sex differences
in adenosine deaminase activity of stroke patients. Clin
Chem Lab Med. 2008;46:506-509.
- 37. Brann DW, Dhandapani K, Wakade C, et al. Neurotrophic
and neuroprotective actions of estrogen: basic mechanisms
and clinical implications. Steroids 2007;72:381–405.